Granules India Limited has informed the Exchange regarding a press release dated January 08, 2026, titled "CIN: L24110TG1991PLC012471 / Granules India Limited: 15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad 500084, Telangana, India.Press ReleaseGranules Pharmaceuticals, Inc. Receives FDA Tentative Approval with 180-Day Exclusivity for Generic Amphetamine Extended-Release Tablets (gDYANAVEL XR)".
Press Release Jan 08 2026
Filed with NSE · · 3 pages · English
Watch Granules India's latest callGranules India (NSE:GRANULES) Q2 2027 Earnings Call · Replay · Nov 2Read the transcript of Granules India (NSE:GRANULES) Q2 2027 Earnings CallRelease
Earlier from Granules India
- Press Release Dec 22 2025
- Press Release Dec 04 2025
- Press Release Dec 01 2025
- Press Release Nov 13 2025
- Press Release Nov 11 2025
Later from Granules India
- Q3FY26 Revenue from operations at INR 13,879 Mn up 22% YoY, EBITDA at INR 3,081 Mn up 34% YoY, PBT at INR 2,022 Mn up 32% YoY, PAT at INR 1,502 Mn up 28% YoY.
- Press Release Jan 23 2026
- Press Release Mar 05 2026
- Press Release Mar 31 2026
- Press Release Apr 04 2026
Follow Granules India into a list and get an email when it puts out news.
Follow Granules India